Filter
21
Filtered Results: 21
Text search:
European
&
Developing
Countries
Clinical
Trials
Partnership
EDCTTP
Featured
Recommendations
1
New Publications
1
Language
Document type
Studies & Reports
8
No document type
7
Fact sheets
3
Strategic & Response Plan
2
Guidelines
1
Countries / Regions
Global
3
Mozambique
2
West and Central Africa
2
East and Southern Africa
2
Kenya
1
Burkina Faso
1
Middle East and North Africa
1
Ethiopia
1
Authors & Publishers
Publication Years
Category
Studies & Reports
2
Disaster Preparedness
1
COVID-19
1
x MEDBOX Issue Brief & Annual Reports x
1
Policies & Guidelines HIV & TB
1
Drugs & Medical Equipment
1
Toolboxes
Vaccines & Immunization
2
Detection & Diagnosis
2
Policies & Strategies
1
Local Action
1
Childhood TB
1
Public Health
1
Mozambique
1
Children
1
Health Equity & Equality
1
International
1
Communication & Training
1
Prevention & Preparedness
1
Studies
1
General
1
Global Impact: Socio-economic, health services, TB & HIV
1
TB/COVID-19
1
Research & Pipeline
1
Strategies & Roadmaps
1
Studies & Reports
1
Studies & Reports
1
Overview, Studies & Reports
1
General Information & Methodology
1
Health Financing Toolbox
1
TB & Prisoners
1
Training
1
Research & Access
1
PLOS ONE 10(12): e0144040. doi:10.1371/journal.pone.0144040
Policy
25 February 2015 Vol 7 Issue 276 276fs8
This study aimed to understand the patterns of HIV drug resistance in pregnant women in Mozambique. This might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care.
This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Mozambique.
BMC Infectious Diseases (2016) 16:423 DO...
Robust clinical research capacity in low- and middle-income countries is key to stemming the spread of epidemics, according to a new report from the International Vaccines Task Force (IVTF). The report lays out how to develop the political support, financing and coordination required to build this c...
The World Health Organization (WHO) has recommended a universal antiretroviral therapy (ART) for all HIVinfected children before the age of two since 2010, but this implies an early identification of these infants. We described the Prevention of Mother-to-Child HIV Transmission (PMTCT) cascade, the ...
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac...
An Action Framework and annexe to Immunization Agenda 2030 (Draft version)
27 January 2021
How to address the global crisis in antibiotic research and development.
The report includes a comprehensive summary and critical evaluation of recent initiatives to overcome the barriers to achieve sustainable access to antibiotics. As antibiotic resistance will continue to develop as long as we ...
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij...
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
The roadmap describes the actions needed to
achieve the three development goals for TB
vaccines set by the WHO:
1. A safe, effective and affordable TB vaccine
for adolescents and adults.
2. An affordable TB vaccine for neonates and
infants with improved safety and efficacy.
3. A therapeutic v...
Tuberculosis (TB)
recommended
MEDBOX Issue Brief no. 19: World TB Day: Invest to end TB. Save Lives
Learnings from the COVID-19 evidence response and recommendations for the future.
Reflections and recommendations from the evidence synthesis community.
Since 2000, concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypan...
TDR (Tropical Disease Research) Annual Report 2018
There is an urgent need to build Research and Development (R&D) capacity for leishmaniasis and other neglected tropical diseases (NTDs) in the Middle East and North Africa. The neglected tropical diseases are a group of 17 viral, bacterial, protozoan, and helminthic infections that often have high m...
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
CEPI is seeking to raise $3.5 billion to implement CEPI’s next 5-year plan. To mitigate the immediate threat of COVID-19 variants, it is activating key elements of this plan now—and seeking to mobilise a portion of this $3.5 billion in 2021. We have already launched R&D programmes to initiate de...
Previous advocacy efforts have achieved tangible goals in terms garnering political commitments
to increase financing for TB—as seen at the 2018 UN High-Level Meeting on TB. The challenge
now is to ensure that these commitments are actually met within a global biomedical research
ecosystem that...
